Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Rhea-AI Summary

Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, has announced the pricing of an upsized public offering of 5,000,000 shares of Class A common stock at $100.00 per share. The offering is expected to generate gross proceeds of approximately $500.0 million for Nuvalent. The underwriters have a 30-day option to purchase up to an additional 750,000 shares. The offering is anticipated to close on September 18, 2024, subject to customary closing conditions. J.P. Morgan, TD Cowen, Jefferies, and Stifel are acting as joint book-running managers for the offering.

Positive

• Upsized public offering indicates strong investor demand
• Expected gross proceeds of $500.0 million to strengthen company's financial position
• Additional 30-day option for underwriters to purchase 750,000 more shares

Negative

• Potential dilution of existing shareholders' ownership
• Stock price may face downward pressure due to increased supply of shares

Financial Analyst

Nuvalent's upsized public offering of 5 million shares at $100 per share is a significant capital raise, potentially bringing in $500 million before expenses. This substantial influx of cash could greatly enhance the company's ability to fund its clinical-stage cancer therapies pipeline. The pricing at $100 per share suggests strong investor confidence in Nuvalent's prospects. The additional 30-day option for underwriters to purchase up to 750,000 more shares could further boost the capital raised by $75 million. This financial move strengthens Nuvalent's position in the competitive oncology market and provides a solid runway for advancing its targeted therapies.

Oncology Research Analyst

Nuvalent's focus on precisely targeted therapies for clinically proven kinase targets in cancer aligns with the cutting-edge trends in oncology research. The substantial capital raised through this offering could accelerate the development of their pipeline, potentially bringing innovative treatments to market faster. This is particularly important in the rapidly evolving field of targeted cancer therapies, where speed to market can be crucial. The investor confidence reflected in this successful offering suggests that Nuvalent's approach to kinase inhibition is viewed favorably by the market, which could translate to increased interest from potential partners or collaborators in the oncology space.

Market Research Analyst

The successful pricing of Nuvalent's upsized offering indicates strong market demand for biopharmaceutical companies focused on targeted cancer therapies. The involvement of major underwriters like J.P. Morgan and Jefferies further validates the company's market position. The timing of this offering is noteworthy, coming amidst a challenging economic environment, suggesting that investors are still eager to back promising biotech firms despite broader market uncertainties. This successful raise could potentially trigger increased investor interest in the oncology sector, particularly for companies developing precision medicine approaches. It's a positive signal for the biotech industry, demonstrating that well-positioned companies can still access significant capital in the public markets.

CAMBRIDGE, Mass., Sept. 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of an upsized underwritten public offering of 5,000,000 shares of Class A common stock at a price to the public of $100.00 per share. All shares are being offered by Nuvalent. The gross proceeds to Nuvalent from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $500.0 million. The offering is expected to close on September 18, 2024, subject to the satisfaction of customary closing conditions. In addition, the underwriters have a 30-day option to purchase up to an additional 750,000 shares of Class A common stock at the public offering price less underwriting discounts and commissions.

J.P. Morgan, TD Cowen, Jefferies and Stifel are acting as joint book-running managers for the offering.

The shares are being offered by Nuvalent pursuant to an automatically effective shelf registration statement that was filed with the Securities and Exchange Commission ("SEC") on March 16, 2023. The offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC's website at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus can be obtained, when available, from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (855) 495-9846 or by email at TD.ECM_Prospectus@tdsecurities.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at 415-364-2720 or by email at syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that involve substantial risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate," "seek," "look forward," "advance," "goal," "strategy," "promising," "opportunity," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements regarding the proposed offering, including the satisfaction of customary closing conditions relating to the offering and the expected closing of the offering. Actual results may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to market conditions that may affect the timing, terms and conditions of the offering and the satisfaction of closing conditions related to the offering. There can be no assurance that Nuvalent will be able to complete the offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements. Additional risks and uncertainties relating to the offering, Nuvalent and its business can be found under the caption "Risk Factors" included in Nuvalent's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, Nuvalent's preliminary prospectus supplement filed with the SEC on September 16, 2024 and other filings that Nuvalent may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Nuvalent expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-announces-pricing-of-upsized-public-offering-of-common-stock-302249714.html

SOURCE Nuvalent, Inc.

FAQ

What is the price per share for Nuvalent's (NUVL) public offering?

Nuvalent (NUVL) has priced its public offering at $100.00 per share of Class A common stock.

How many shares is Nuvalent (NUVL) offering in its public offering?

Nuvalent (NUVL) is offering 5,000,000 shares of Class A common stock in its upsized public offering.

What are the expected gross proceeds from Nuvalent's (NUVL) public offering?

Nuvalent (NUVL) expects to generate gross proceeds of approximately $500.0 million from its public offering.

When is Nuvalent's (NUVL) public offering expected to close?

Nuvalent's (NUVL) public offering is expected to close on September 18, 2024, subject to customary closing conditions.